Perindopril-d5

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Bhat S A, et al. Angiotensin receptor blockade modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation better than angiotensin-converting enzyme inhibition [J]. Molecular neurobiology, 2016, 53: 6950-6967.|[3]Wei X, et al. Combination of perindopril erbumine and huangqi-danshen decoction protects against chronic kidney disease via sirtuin3/mitochondrial dynamics pathway [J]. Evidence-Based Complementary and Alternative Medicine, 2022, 2022.|[4]Afonso T, et al. Pharmacodynamic evaluation of 4 angiotensin‐converting enzyme inhibitors in healthy adult horses [J]. Journal of veterinary internal medicine, 2013, 27 (5) : 1185-1192.|[5]Thybo N K, et al. Dose-dependent effects of perindopril on blood pressure and small-artery structure [J]. Hypertension, 1994, 23 (5) : 659-666.|[6]Jeffery TK, et al. Perindopril, an angiotensin converting enzyme inhibitor, in pulmonary hypertensive rats: comparative effects on pulmonary vascular structure and function. Br J Pharmacol. 1999 Dec;128 (7) :1407-18.|[7]Xiong F, et al. Inhibition of AAA in a rat model by treatment with ACEI perindopril. J Surg Res. 2014 Jun 1;189 (1) :166-73.